Cryoablation needles
Total Payments
$536,754
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $101,790 | 1 | 0 |
| 2023 | $434,964 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $536,754 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Strategic Collabration Agreement | Boston Scientific Corporation | $425,000 | 0 |
| A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer | Boston Scientific Corporation | $101,790 | 0 |
| A Multicenter Single Arm Open Label Phase II Trial of Cryoablation in Combination with Pembrolizumab in Patients with Metastatic Urothelial Carcinoma | Boston Scientific Corporation | $9,964 | 0 |
Top Doctors Receiving Payments for Cryoablation needles
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $536,754 | 3 |
Ad
Manufacturing Companies
- Boston Scientific Corporation $536,754
Product Information
- Type Device
- Total Payments $536,754
- Total Doctors 0
- Transactions 3
About Cryoablation needles
Cryoablation needles is a device associated with $536,754 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2023 to 2024. In 2024, $101,790 was paid across 1 transactions to 0 doctors.
The most common payment nature for Cryoablation needles is "Unspecified" ($536,754, 100.0% of total).
Cryoablation needles is associated with 3 research studies, including "Strategic Collabration Agreement" ($425,000).